Aurobindo Pharma Subsidiary's US FDA Inspection Concludes with 3 Observations

Aurobindo Pharma Ltd has announced the completion of a US FDA inspection at Unit-VI of its wholly-owned subsidiary, Apitoria Pharma Private Limited. The inspection, which took place from August 24 to August 28, 2026, at the API manufacturing facility in Andhra Pradesh, concluded with three procedural observations. The company stated it will respond to the US FDA within the stipulated timeline and is committed to maintaining high quality and compliance standards. Further developments will be communicated as required.